Cancer Treatment and Research Communications (Jan 2023)

Immunotherapy for the elderly. Maybe the best option for lung cancer?

  • Paul Zarogoulidis,
  • Dimitris Matthaios,
  • Panagoula Oikonomou,
  • Christina Nikolaou,
  • Charalampos Charalampidis,
  • Chrysanthi Sardeli

Journal volume & issue
Vol. 37
p. 100762

Abstract

Read online

Lung cancer is usually diagnosed at advanced stage and systematic therapy is administered. New current diagnostic techniques such as the convex-endobronchial ultrasound, radial endobronchial ultrasound, cone beam ct, electromagnetic navigation and robotic bronchoscopy provide us with a high diagnostic yield. These techniques are minimal invasive and patients with comorbidities such as chronic obstructive pulmonary disease and heart failure can be diagnosed with minimal adverse effects. All these techniques provide sufficient sample for molecular investigation. Since immunotherapy was first administered, we have more and more information regarding the appropriate patient target group. Several published studies divided patients as elderly ≥75 and non-elderly ≤74 and investigated the adverse effects of different drugs and survival. In our current commentary we present information on patients receiving immunotherapy versus chemoimmunotherapy in two groups of elderly and non-elderly. Elderly patients can receive both combinations without differences between the two groups, however; more studies are needed to clarify certain aspects.

Keywords